Your browser doesn't support javascript.
loading
Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q.
Jhaveri, K L; Wang, X V; Makker, V; Luoh, S-W; Mitchell, E P; Zwiebel, J A; Sharon, E; Gray, R J; Li, S; McShane, L M; Rubinstein, L V; Patton, D; Williams, P M; Hamilton, S R; Conley, B A; Arteaga, C L; Harris, L N; O'Dwyer, P J; Chen, A P; Flaherty, K T.
Affiliation
  • Jhaveri KL; Department of Medicine, Memorial Sloan-Kettering Center, New York. Electronic address: jhaverik@mskcc.org.
  • Wang XV; Biostatistics, E-A Biostatistical Center, Boston.
  • Makker V; Gynecologic Medical Oncology Service, Memorial Sloan-Kettering Cancer Center, New York.
  • Luoh SW; Knight Cancer Institute, Oregon Health Science University, Portland.
  • Mitchell EP; Medical Oncology, Thomas Jefferson University, Philadelphia.
  • Zwiebel JA; Investigational Drug Branch, Division of Cancer Treatment and Diagnosis.
  • Sharon E; Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda.
  • Gray RJ; Department of Biostatistics, Dana Farber Cancer Institutes, Boston.
  • Li S; Department of Biostatistics, Dana Farber Cancer Institutes, Boston.
  • McShane LM; Biometric Research Branch, National Cancer Institute, Bethesda.
  • Rubinstein LV; Biometric Research Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institute of Health, Bethesda.
  • Patton D; Center for Biomedical, Informatics & Information Technology, National Cancer Institute, Bethesda.
  • Williams PM; Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, Frederick.
  • Hamilton SR; Department of Pathology, University of Texas MD Anderson Cancer Center, Houston.
  • Conley BA; Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda.
  • Arteaga CL; Department of Internal Medicine, University of Texas Southwestern, Dallas.
  • Harris LN; Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda.
  • O'Dwyer PJ; University of Pennsylvania, Philadelphia.
  • Chen AP; CTEP, National Cancer Institute, Bethesda.
  • Flaherty KT; Cancer Center, Massachusetts General Hospital, Boston, USA.
Ann Oncol ; 30(11): 1821-1830, 2019 11 01.
Article in En | MEDLINE | ID: mdl-31504139
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Biomarkers, Tumor / Receptor, ErbB-2 / Antineoplastic Agents, Immunological / Ado-Trastuzumab Emtansine / Neoplasms Limits: Adult / Aged / Aged80 / Female / Humans / Middle aged Country/Region as subject: America do norte Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2019 Document type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Biomarkers, Tumor / Receptor, ErbB-2 / Antineoplastic Agents, Immunological / Ado-Trastuzumab Emtansine / Neoplasms Limits: Adult / Aged / Aged80 / Female / Humans / Middle aged Country/Region as subject: America do norte Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2019 Document type: Article